HOLIDAY SHIPPING UPDATE: All delivery service requests will not be processed on Friday April 2, 2021 as it is Good Friday holiday. Regular delivery schedule will resume the next business day.
Anti-phospho-KDR (Tyr1214)(K01-65BR)

Anti-phospho-KDR (Tyr1214)(K01-65BR)

  • $325.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :Rabbit Polyclonal Antibody

Species :

Tag :

Expression System:

Sequence :

Specificity :Recognizes the KDR protein phosphorylated at tyrosine 1214

Cited Applications :IHC

Cross Reactivity :Human and Mouse

Host / Isotype / Clone# :Rabbit, IgG

Immunogen :Synthetic phospho-peptide corresponding to amino acid residues surrounding Tyr1214

Purification :Affinity chromatography

Stability :Store at 4oC (add 0.1% NaN3) for several months, and at -20oC for longer periods. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Sample Data :Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using phosphor-KDR (Tyr1214) antibody.

Scientific Background :Kinase insert domain receptor (KDR or VEGFR) is a growth factor receptor tyrosine kinase that plays a pivotal role in endothelial cell proliferation and differentiation. KDR binds VEGF with high affinity and this interaction is implicated in angiogenesis (1). The expression levels of VEGF and KDR are highly correlated during the normal development of the ocular vasculature in humans (1). Induction of angiogenesis is a critical step in tumor progression, and inhibitors of KDR have been demonstrated both to promote tumor regression and reduce metastatic potential in preclinical studies (2). Autophosphorylation of KDR occurs at Tyr951, Tyr996, Tyr1054 and Tyr1059 and phosphorylation at Tyr1214 is associated with interactions with downstream effector molecules (3).

References  :
1. Neufeld, G. et al: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999 Jan;13(1):9-22.

2. Zhu, Z. et al: Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs. 1999;17(3):195-212.

3. Lamalice L. et al: Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF. J Biol Chem. 2006 Nov 10;281(45):34009-20.

Product Sheets (By Lot #) :

J1178-16.pdf

Research Areas :AKT/PKB Pathway, Angiogenesis, Apoptosis/Autophagy, Cancer, Cardiovascular Disease, ERK/MAPK Pathway, Inflammation, p38 Pathway, Receptor Tyrosine Kinases, Cancer, Inflammation, Cardiovascular Disease, AKT/PKB Pathway, ERK/MAPK Pathway, p38 Pathway, Apoptosis/Autophagy, Angiogenesis, Receptor Tyrosine Kinases